medigraphic.com
Academia Mexicana de Neurología, A.C.

2013, Número 6

<< Anterior Siguiente >>

Rev Mex Neuroci 2013; 14 (6)


Relevancia de la pérdida de volumen cerebral en la esclerosis múltiple e impacto de las terapias modificadoras de la enfermedad en la reducción de la pérdida de volumen cerebral

Mendoza-Bernal JA, Jiménez-González ME, Chiquete E, González-HIF

Idioma: Español
Referencias bibliográficas: 47
Paginas: 341-348
Archivo PDF: 207.11 Kb.


RESUMEN

La pérdida de tejido cerebral de los pacientes con esclerosis múltiple (EM) es hasta cuatro veces mayor a la que ocurre en sujetos sanos por el proceso normal de envejecimiento. Los tratamientos modificadores de la enfermedad (TME) están enfocados de manera principal a controlar la inflamación. No obstante, los análogos de esfingosina han mostrado tener un efecto de clase en la reducción de la progresión de la pérdida de tejido cerebral. Esto abre un nuevo horizonte en las metas de tratamiento de pacientes con EM, no sólo en su manejo durante las fases iniciales de inflamación activa, sino también en las formas crónicas en las que existe pérdida acelerada de tejido cerebral. El objetivo de esta revisión narrativa es la de discutir el papel de los TME emergentes en la prevención de la atrofia cerebral en pacientes con EM y, en particular, de fingolimod, el análogo de esfingosina disponible actualmente en el mercado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Koch-Henriksen N., Sorensen S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-32.

  2. Alter M, Olivares L. Multiple sclerosis in Mexico. An epidemiologic study. Arch Neurol 1970; 23: 451-9.

  3. Rodríguez García A, Sotelo Morales J. [Multiple sclerosis in Mexico]. Salud Publica Mex 1981; 23: 451-6.

  4. Gonzalez O, Sotelo J. Is the frequency of multiple sclerosis increasing inMexico? J Neurol Neurosurg Psychiatry 1995; 59: 528-30.

  5. Corona T, Rodrigues JL, Otero E, Stopp L. Multiple sclerosis in Mexico:hospital cases at the National Institute of Neurology and Neurosurgery, Mexico City. Neurologia 1996; 11: 170-3.

  6. De la Maza M, García J, Bernal J, Fuentes M. [A review of the epidemiology of multiple sclerosis in Mexico]. Rev Neurol 2000; 31: 494-5.

  7. Velázquez-Quintana M, Macías-Islas MA, Rivera-Olmos V, Lozano- Zárate J.[Multiple sclerosis in Mexico: a multicentre study]. Rev Neurol 2003; 36: 1019-22.

  8. Cordova J, Vargas S, Sotelo J. Western and Asian features of multiple sclerosis in Mexican Mestizos. Clin Neurol Neurosurg 2007; 109: 146- 51.

  9. Aguirre-Cruz L, Flores-Rivera J, De La Cruz-Aguilera DL, Rangel- López E, Corona T. Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity 2011; 44: 571-5.

  10. Magaña-Zamora L, Chiquete E, Campos-González ID, Cantú-Lela R, Ibarra-Bravo O, Punzo-Bravo G, et al. Factores de riesgo y pronóstico de pacientes con esclerosis múltiple del estado de Michoacán, México: Un estudio de casos y controles. Rev Mex Neuroci 2012;13: 78-85.

  11. Barten LJ, Allington DR, Procacci KA, Rivey MP. New approaches in the management of multiple sclerosis.Drug Des Devel Ther 2010; 4: 343-66.

  12. Macías-Islas MA, Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Baca-Muro VI, Lemus-Carmona EA, et al. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg 2013 [Epub ahead of print]

  13. Shiee N, Bazin PL, Zackowski KM, Farrell SK, Harrison DM, Newsome SD, et al. Revisiting Brain Atrophy and Its Relationship to Disability in Multiple Sclerosis. Plos One 2012; 7: e37049.

  14. Eshaghi A, Bodini B, Ridgway GR, García-Lorenzo D, Tozer D, Sahraian MA, et al. Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. Neuroimage 2013; S1053- 8119(13)00995-6.

  15. Perumal J, Khan O. Emerging disease-modifying therapies in multiple sclerosis. Curr Treat Options Neurol 2012; 14:256-63.

  16. Fernandez O, Alvarez-Cermeno JC, Arroyo-Gonzalez R, Brieva L, Calles-HernandezMC, Casanova-Estruch B, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol 2012; 54:734-49.

  17. Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013; 328: 9-18.

  18. García-Merino JA, Sánchez AJ. [Basic mechanisms of action of fingolimod inrelation to multiple sclerosis]. Rev Neurol 2012; 55: 31-7.

  19. Cohen J, Radue EW, Barkhof F, Kappos L, Calabresi P, Haering D, et al. Fingolimod-Effect on Brain Atrophy and Clinical/MRI Correlations in Three Phase 3 Studies-TRANSFORMS, FREEDOMS and FREEDOMS II (S51.006). Neurology 2013; 80: S51.006.

  20. Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2013[Epub ahead of print].

  21. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-66.

  22. Yao Z, Hu B, Liang C, Zhao L, Jackson M. Alzheimer’s Disease Neuroimaging Initiative. A Longitudinal Study of Atrophy in Amnestic Mild Cognitive Impairment and Normal Aging Revealed by Cortical Thickness. PLoS One 2012; 7: e48973.

  23. Simon JH. Brain atrophy in multiple sclerosis: what we know and would like to know. Mult Scler 2006; 12: 679-87.

  24. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5: 158-70.

  25. Montalban X, Comi G, Antel J, O’Connor P, de Vera A, Cremer M, et al. Long-term (> 7-year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Póster presentado en ENS 2012, 9-12 June, 2012, Prague, Czech Republic.

  26. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosur Psychiatr 1962; 25: 315-20.

  27. Horakova D, Kalincik T, Dusankova JB, Dolezal O. Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurology 2012; 12: 10.

  28. Cadavid D, Tang Y, O’Neill G. [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention inprogressive forms of multiple sclerosis]. Rev Neurol 2010; 51: 321-9.

  29. Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 1082-91.

  30. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, et al. Corticallesions and atrophy associated with cognitive impairment in relapsing-remittingmultiple sclerosis. Arch Neurol 2009; 66: 1144-50.

  31. Lukas C, Minneboo A, de Groot V, Moraal B, Knol DL, Polman CH, et al. Early central atrophy rate predicts 5 year clinical outcome inmultiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 1351-6.

  32. Prinster A, Quarantelli M, Lanzillo R, Orefice G, Vacca G, Carotenuto B, et al. A voxel-based morphometry study of disease severity correlates in relapsing- remitting multiple sclerosis. Mult Scler 2010; 16: 45-54.

  33. Barkhof F, Filippi M. MRI—the perfect surrogate marker for multiple sclerosis? Nat Rev Neurol 2009; 5: 182–3.

  34. Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004; 14: 27S-35S.

  35. Filippi M, Rocca MA, Benedict RH, De Luca J, Geurts JJ, Rombouts SA, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010; 75: 2121-8.

  36. Flores-Rivera JJ. Fingolimod: Una novedosa terapia, modulador de los receptores de esfingosina para las formas recurrentes de esclerosis múltiple. Rev Mex Neuroci. 2010; 11: 250-61.

  37. Jackson SJ, Giovannoni G, Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation 2011; 8: 76.

  38. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.

  39. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.

  40. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophyin multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676-95.

  41. Zivadinov R, Reder AT, Filippi M, Minagar A, Stüve O, Lassmann H, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136-44.

  42. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomizedtrial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-303.

  43. Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, et al. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opin Pharmacother 2013; 14: 2145-56.

  44. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.

  45. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effect oflaquinimod on MRI-monitored disease activity in patients with relapsing-remittingmultiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-92.

  46. Radue EW, Goodin D, Jeffery D, et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing–remitting multiple sclerosis: results from the phase 3 FREEDOMS-II study. Poster presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012; Lyon, France. P724.

  47. Radue EW, O’Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 2012; 69: 1259-69.




2020     |     www.medigraphic.com